Relay Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Stockholders held by Relay Therapeutics, Inc. on May 31, 2023. The filing details the voting outcomes for three specific proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1: Election of Directors. Stockholders elected three Class III directors for a three-year term ending in 2026.
- Douglas S. Ingram: 103,319,668.59 votes for; 1,429,573.00 votes withheld.
- Sekar Kathiresan, M.D.: 104,644,413.59 votes for; 104,828.00 votes withheld.
- Jami Rubin: 94,814,052.83 votes for; 9,935,188.75 votes withheld.
- Proposal 2: Executive Compensation (Say-on-Pay). Stockholders approved the non-binding advisory vote on executive compensation.
- Votes For: 97,777,468.59
- Votes Against: 6,901,684.00
- Abstain: 70,089.00
- Proposal 3: Ratification of Auditors. Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Votes For: 112,171,015.00
- Votes Against: 11,640.00
- Abstain: 40,019.00
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to calculate the percentage of votes cast for each proposal.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 21, 2023) for detailed biographies of the elected directors and the rationale behind the executive compensation package.
- Confirm the term end date for the newly elected Class III directors is the 2026 annual meeting.